EphA5 Silencing Increases the Radiosensitivity of ESCC Cells Through ATM-Dependent Pathway.

Szczegóły
Abstrakt

Tytuł:: EphA5 Silencing Increases the Radiosensitivity of ESCC Cells Through ATM-Dependent Pathway.
Autorzy:: Zhang R; Department of Oncology, QingPu Branch of Zhongshan Hospital Affiliated to Fudan University, Shanghai 201799, People's Republic of China.
Han D; Division of Life Science and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, People's Republic of China.
Li L; Division of Life Science and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, People's Republic of China.
Luo W; Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, People's Republic of China.
Liu J; Department of Pathology, Qing Pu Branch of Zhongshan Hospital Affiliated to Fudan University, Shanghai 201799, People's Republic of China.
Qian L; Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, People's Republic of China.
Źródło:: Cancer management and research [Cancer Manag Res] 2020 Oct 02; Vol. 12, pp. 9539-9549. Date of Electronic Publication: 2020 Oct 02 (Print Publication: 2020).
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Original Publication: [Auckland, N.Z.] : Dove Medical Press, c2009-
References:: Cytometry A. 2015 Aug;87(8):717-23. (PMID: 26087127)
World J Surg. 1992 Nov-Dec;16(6):1104-9; discussion 1110. (PMID: 1455880)
Ann Surg. 2005 Oct;242(4):566-73; discussion 573-5. (PMID: 16192817)
Cancer Cell Int. 2020 Jan 13;20:20. (PMID: 31956298)
Arch Surg. 1992 Dec;127(12):1446-50. (PMID: 1365692)
Lancet Oncol. 2005 Sep;6(9):659-68. (PMID: 16129366)
J Thorac Cardiovasc Surg. 1988 Aug;96(2):242-8. (PMID: 2456424)
J Ovarian Res. 2016 Nov 25;9(1):83. (PMID: 27887627)
J Thorac Cardiovasc Surg. 1997 Aug;114(2):210-7. (PMID: 9270638)
J Surg Oncol. 1994 Jul;56(3):191-7. (PMID: 7518020)
Surgery. 1993 Feb;113(2):138-47. (PMID: 8430362)
Cochrane Database Syst Rev. 2006 Jan 25;(1):CD002092. (PMID: 16437440)
Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):928-42. (PMID: 15234026)
FASEB J. 2019 Apr;33(4):4851-4865. (PMID: 30620624)
Zhonghua Zhong Liu Za Zhi. 2001 May;23(3):254-5. (PMID: 11783101)
Cell. 1997 Aug 8;90(3):403-4. (PMID: 9267020)
Dtsch Med Wochenschr. 1984 Mar 23;109(12):450-3. (PMID: 6705695)
Ann Thorac Surg. 2003 Feb;75(2):331-6. (PMID: 12607634)
Hum Pathol. 2010 Jan;41(1):48-58. (PMID: 19733895)
J Biol Chem. 2015 Mar 20;290(12):7345-59. (PMID: 25623065)
Dis Esophagus. 2000;13(2):136-41. (PMID: 14601905)
World J Surg. 1995 May-Jun;19(3):444-9. (PMID: 7639004)
N Engl J Med. 1998 Dec 31;339(27):1979-84. (PMID: 9869669)
Front Genet. 2013 Mar 25;4:37. (PMID: 23532176)
Nat Rev Cancer. 2010 Mar;10(3):165-80. (PMID: 20179713)
N Engl J Med. 1996 Aug 15;335(7):462-7. (PMID: 8672151)
Cancer. 1994 Apr 1;73(7):1779-84. (PMID: 8137201)
Mol Cell. 2010 Oct 22;40(2):179-204. (PMID: 20965415)
BMC Cancer. 2015 Jan 22;15:18. (PMID: 25609195)
Br J Surg. 2010 Oct;97(10):1482-96. (PMID: 20645400)
DNA Repair (Amst). 2016 Mar;39:1-20. (PMID: 26777338)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
Ann Oncol. 2004 Jun;15(6):947-54. (PMID: 15151953)
Histol Histopathol. 2017 May;32(5):491-497. (PMID: 27651378)
J Biol Chem. 2001 Nov 9;276(45):42462-7. (PMID: 11571274)
Lancet. 2002 May 18;359(9319):1727-33. (PMID: 12049861)
Dis Esophagus. 2016 Oct;29(7):707-714. (PMID: 27731549)
J Clin Oncol. 2001 Jan 15;19(2):305-13. (PMID: 11208820)
Cancer. 2001 Jun 1;91(11):2165-74. (PMID: 11391598)
N Engl J Med. 1997 Jul 17;337(3):161-7. (PMID: 9219702)
Pathol Oncol Res. 2010 Jun;16(2):267-76. (PMID: 19949912)
Oncol Lett. 2019 Jun;17(6):5147-5153. (PMID: 31186729)
Contributed Indexing:: Keywords: ATM; EphA5; esophageal squamous cell carcinoma; radiosensitivity
Entry Date(s):: Date Created: 20201016 Latest Revision: 20220417
Update Code:: 20240105
PubMed Central ID:: PMC7537809
DOI:: 10.2147/CMAR.S261182
PMID:: 33061640
: Czasopismo naukowe

Full Text Finder

Background: Radiotherapy is one of the most important treatments for esophageal squamous cell carcinoma (ESCC). Previously, we found that EphA5 expression was increased in ESCC cells and tumor tissues. Studies from other groups reported that EphA5 is abnormally expressed in numerous malignant tumors and may be involved in the radiosensitivity of lung cancer. However, the role of EphA5 in radiotherapy for ESCC remains unclear.
Methods: The siRNA sequences against human EPHA5 were transfected to the ESCC cells (KYSE150 and KYSE450). After ionizing radiation (IR), cell viability and colony formation assays were used to test the changes of cell proliferation in EphA5-silenced cells. Flow cytometry analysis was performed to investigate the cell apoptosis and cycle in the irradiated cells interfered by siRNA. The key molecules involved in cell cycle checkpoints and DNA damage repair were evaluated by Western blot and immunofluorescence.
Results: CCK8 assay and clonogenic assay showed that the proliferation of EphA5-silenced ESCC cells was inhibited after IR. At 24 h post-IR treatment, we found that the G1/S checkpoint triggered by DNA damage in EphA5-silenced cells was defective. γ-H2AX foci in the irradiated EphA5-silenced cells were impaired at 0.5 h post-IR treatment as well as ATM activation. The defective activation of ATM resulted in a decrease of p-Chk2, p-p53 and p21 expression.
Conclusion: In conclusion, these results indicate that EphA5 silencing increases radiosensitivity in ESCC cells through ATM-dependent pathway, which provides a potential target for the radiotherapy in ESCC.
Competing Interests: The authors report no conflicts of interest for this work.
(© 2020 Zhang et al.)

Informacja